Clinical Trials Directory

Trials / Completed

CompletedNCT00004875

Heparin or Enoxaparin in Patients With Cancer

Release of TFPI by Anticoagulants in Cancer Patients by Standard or LMW Heparin

Status
Completed
Phase
Study type
Observational
Enrollment
6 (actual)
Sponsor
Northwestern University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Heparin or enoxaparin may be effective in preventing the formation of blood clots in patients with cancer who are undergoing surgery to remove the tumor. PURPOSE: Randomized clinical trial to compare the effectiveness of heparin with that of enoxaparin in patients who have cancer.

Detailed description

OBJECTIVES: I. Determine the patterns of tissue factor pathway inhibitor (TFPI) release according to tumor type and type of anticoagulation (heparin or enoxaparin) in patients with cancer. II. Determine the incidence of portacath clots and its correlation to TFPI releasability in this patient population. III. Compare these anticoagulation drugs in terms of releasability of TFPI in this patient population. OUTLINE: This is a randomized study. Patients are stratified according to prior chemotherapy within the past 3 weeks (yes vs no). Patients are randomized to one of two treatment arms. Arm I: Patients receive a single dose of standard heparin subcutaneously (SQ) followed by evaluation of tissue factor pathway inhibitor (TFPI) response at 5 and 10 minutes post injection. Arm II: Patients receive a single dose of enoxaparin SQ followed by evaluation of TFPI response as in arm I. Patients are followed monthly for 3 months. PROJECTED ACCRUAL: A total of 20-200 patients will be accrued for this study over 6 months.

Conditions

Interventions

TypeNameDescription
DRUGenoxaparin
DRUGheparin

Timeline

Start date
1996-07-01
Primary completion
1999-03-01
Completion
1999-03-01
First posted
2004-07-26
Last updated
2011-02-21

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00004875. Inclusion in this directory is not an endorsement.